Merck & Co. (MRK)
(Delayed Data from NYSE)
$93.13 USD
+1.13 (1.23%)
Updated Jun 24, 2022 04:06 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Price, Consensus and EPS Surprise
MRK 93.13 +1.13(1.23%)
Will MRK be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for MRK based on the 1-3 month trading system that nearly triples the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MRK
Pharma Stock Roundup: FDA OK's Expanded Use of ABBV, MRK, NVS Drugs, Other Updates
Merck's (MRK) Pneumococcal Vaccine Gets FDA Nod for Kids
MRK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Merck (MRK) Gains As Market Dips: What You Should Know
Iovance (IOVA) Pipeline Aids Growth Amid Lack of Marketed Drugs
Seagen (SGEN) Stock Up on Rumors of Acquisition by Merck
Other News for MRK
3 Dow Stocks to Buy for a Bear Market
What You Missed On Wall Street This Morning
EMA panel recommends extending indications for Merck`s Zerbaxa medicine to include kids
Merck - Seagen deal clouded by questions over regulatory risk, valuation - BMO
Fly Intel: Pre-market Movers